The real test for healthtech companies isn’t innovation – it’s implementation

For much of the past decade, the pharmaceutical industry has been immersed in discussions about digital transformation. Artificial intelligence, digital therapeutics, and TechBio platforms have promised to reshape how medicines are discovered, developed, and delivered.

But the tone of that conversation is beginning to shift from promise to performance. It’s no longer whether these technologies will transform healthcare, it’s whether they can be implemented at scale within the complex structures of healthcare systems and pharmaceutical organisations.

Few places showcase this shift better than the Basel region of Switzerland. Long recognised as one of the world’s most important pharmaceutical hubs, the Basel Area is increasingly becoming a convergence point where life sciences, advanced computing, and health technology intersect. What makes the region particularly interesting today is not only its scientific depth, but how its ecosystem is evolving to translate innovation into real-world applications.

From cluster to collaborative supercluster

The Basel Area has long benefitted from extraordinary density in life sciences. It’s where global pharmaceutical companies operate alongside leading academic institutions, hospitals, and a thriving biotech community. What has changed more recently is how that proximity is being used.

Collaboration between pharmaceutical companies, research institutions, and technology-driven ventures has become more structured and visible. Across the region, organisations are building stronger translational bridges between research and industry, helping new discoveries move more efficiently toward practical use.

One example is the collaboration between Personalized Health Basel and biotech giant Roche on synthetic clinical data, which illustrates how the ecosystem is beginning to combine scientific excellence with industrial implementation. The partnership aims to transform the Basel region into a leading hub for personalised healthcare by streamlining data-driven clinical and research processes, fostering relationships between academia and industry, and facilitating interdisciplinary and translational collaboration.

This partnership reflects a broader maturation of the Basel Area Life Sciences Supercluster. Rather than focusing primarily on early-stage experimentation, the region is increasingly becoming a place where innovation can be validated, tested, and deployed within real healthcare and pharmaceutical environments.

The convergence shaping healthtech

Another defining characteristic of the Basel Area’s transformation is the convergence of life sciences with emerging technology capabilities. While the region is traditionally recognised as a pharmaceutical centre, it is also part of a broader Swiss landscape gaining prominence in areas such as artificial intelligence, advanced computing, and emerging technologies. This convergence is becoming increasingly important as healthtech evolves. The next generation of healthcare innovation will depend on the integration of biology, software, and data science.

Equally important is the infrastructure required to support this transformation. Exchanging electronic health information using modern web technologies like OpenEHR, alongside the increasing adoption of fast healthcare interoperability resources, is helping lay the foundations for scalable digital health solutions.

Together, these developments position the Basel Area not simply as a life sciences hub, but as an environment where future healthcare models can be built and tested.

This shift is also being reinforced by the scale of infrastructure investment now taking place within the industry. Recently, Roche has invested heavily in thousands of advanced AI chips from NVIDIA to accelerate drug development, underscoring a broader move toward building in-house computational capabilities. This kind of investment signals a meaningful transition where AI in pharma is no longer confined to experimentation or external partnerships, but is becoming embedded within core R&D operations. It also raises the bar for the ecosystem, as start-ups and collaborators must now demonstrate not just innovation, but clear, differentiated value that can integrate into increasingly sophisticated internal environments.

From inspiration to implementation

This shift towards implementation was evident in conversations at the 2026 health.tech global summit in Basel, which brought together nearly 6,000 participants from across healthcare, technology, and life sciences. Several themes dominated discussions throughout the event, particularly the role of artificial intelligence, the challenges of scaling innovation, and the growing urgency around adoption.

Perhaps the most striking change in tone was that the conversation around AI has clearly moved beyond early enthusiasm. Industry leaders were no longer asking whether AI matters. Instead, they were asking how organisations can embed it into real operational processes across hospitals, diagnostics, prevention programs, and pharmaceutical development.

Topics ranged from generative AI in clinical care and the validation of AI-enabled medical software to cybersecurity resilience, interoperability, and the integration of genomics and multi-omics into routine care.

Across these discussions, a consistent theme emerged: the industry must move beyond isolated pilot projects and begin building end-to-end systems that can operate reliably within complex healthcare environments.

The innovation bottleneck: Implementation

Despite rapid technological progress, the pharmaceutical industry still faces a familiar challenge: translating innovation into operational reality. The first wave of AI-driven enthusiasm produced a large number of pilot collaborations across healthcare and life sciences. While many delivered promising insights, far fewer progressed to full-scale deployment.

The reasons are rarely technological. More often, the challenge lies in integration, aligning new tools with existing workflows, data systems, regulatory frameworks, and organisational culture. This implementation gap has become one of the defining tensions in the healthtech landscape. Increasingly, industry leaders recognise that the real barrier to digital transformation is not innovation itself, but the ability of organisations to adopt and operationalise it.

A more disciplined approach to start-up collaboration

A growing focus on execution is also reshaping how pharmaceutical companies engage with start-ups. Early enthusiasm around AI led many organisations to experiment broadly with technology partnerships. Today, however, collaborations are becoming more targeted. Pharmaceutical companies are increasingly prioritising solutions that address clearly defined challenges, particularly within research workflows and clinical development.

This means start-ups must now demonstrate greater maturity before partnerships begin. Solutions need to integrate into existing systems, align with organisational processes, and deliver measurable improvements.

The bar is higher, but the collaborations that do emerge are often more meaningful.

Where innovation may scale fastest

While AI in drug discovery continues to attract the largest investment flows, another area of healthtech is gaining increasing attention: clinical development. The economics of drug development explain why.

Although discovery remains critical, most of the time, cost and risk in pharmaceutical pipelines occur during the clinical phases. Improving efficiency at this stage can therefore generate outsized value.

As a result, start-ups working on clinical trial success prediction, patient recruitment, regulatory submissions, and trial management are attracting growing interest from pharmaceutical companies.

There is also increasing focus on novel biomarkers and companion diagnostics, further expanding the technological landscape shaping clinical development.

In many ways, this reflects a natural balancing effect within the innovation system. Producing more candidate molecules is only valuable if there are equally effective ways to test and prioritise them.

The next phase of healthtech ecosystems

The next 12 to 24 months will likely determine which healthtech ecosystems can move beyond innovation density and become true engines of implementation. The ecosystems that succeed will be those able to act as integration points – bringing together the stakeholders needed to validate solutions, test them in real-world settings, and scale them effectively.

For start-ups, sustainability will increasingly depend on defensibility. Competitive advantage will come from assets that are difficult to replicate: privileged access to data, proprietary models with measurable performance advantages, intellectual property, and regulatory traction.

At the same time, advances in agentic AI may reshape how pharmaceutical companies approach adoption of technology. As internal capabilities grow, the traditional “build versus buy” dynamic may shift, making external partnerships more selective and strategic.

Why the Basel area matters now

For pharmaceutical leaders outside Switzerland, the Basel area offers a useful window into where the industry may be heading. The region combines global pharmaceutical expertise with strong scientific and clinical capabilities, expanding technology infrastructure, and a collaborative innovation culture that is increasingly focused on implementation. Perhaps most importantly, the ecosystem is evolving from a place where ideas emerge to a place where they can be validated and scaled.

At a moment when the pharmaceutical industry is shifting from experimentation to execution, that capability may prove increasingly important.

About the authors

Ursula Costa is director of innovation and investment at DayOne, where she connects promising healthtech ventures with investors, industry partners, and the broader Basel Area Life Sciences Supercluster. Her work focuses on supporting companies addressing key challenges in pharmaceutical R&D and healthcare, spanning innovation strategy, venture development, and ecosystem building in the Basel region.

Caoimhe Vallely-Gilroy is a pharmaceutical executive and clinical strategy specialist with a background in clinical development and digital health. Through her work with DayOne, she supports healthtech start-ups in scaling solutions within the pharmaceutical industry. She also serves as managing director of the health.tech global summit, where she focuses on accelerating technology adoption across healthcare.